Breescape™ Unveils Game Changing Reversible Cooling Comforter with BlendTek™ Technology for Unparalleled Temperature Control

NEW YORK, March 14, 2025 /PRNewswire/ -- Bedsure, no. 1 online bedding brand in America^[i], announces the launch of Breescapeâ„¢, a specialized brand engineered for hot sleepers, featuring its proprietary BlendTekâ„¢ technology in the flagship Breescape Reversible Cooling Comforter.

With over 41% of people experiencing night sweats, Breescape - formerly known as the Bedsure Breescape Cooling Series - saw an opportunity to create heat-regulating sleep solutions that provide lasting comfort. Following its successful introduction in March 2024, Breescape products have garnered thousands of raving customer reviews and consistent five-star Amazon ratings. Due to this overwhelming success, Breescape has evolved from a Bedsure product line into an independent brand, solely dedicated to delivering cooler, more comfortable nights through scientifically backed cooling bedding for hot sleepers of all body types.

"The explosive growth of Breescape in just one year validates our dedication to solving real sleep problems and underscores our commitment to innovation," said Eric Lin. "Beyond introducing the Breescape Reversible Cooling Comforter, we're excited to continue using our in-house testing facilities and patented cooling technology to push the boundaries of cooling bedding."

After 23 prototypes and a year of development, the brand perfected BlendTekâ„¢ - an innovative technology fusing advanced fibers in both fabrics and filling to eliminate heat and humidity. To test the fabric, Breescape invited 1,000 hot sleepers, sleep professionals, and sleep technologists to test the new comforter and 91% of them found Breescape's materials cooler than leading other cooling products and 93% found the comforter more breathable throughout the night^[ii]. The BlendTekâ„¢ Technology will make its debut in the new Breescape Reversible Cooling Comforter, which testing has shown to be 3.1x cooler than Bamboo Rayon, 4.5x more breathable than cotton, and 1.5x more moisture-absorbent than cotton. Additional product features include: 

As part of its commitment to offering innovative solutions for uninterrupted sleep, Breescape is proud to be sponsoring the National Sleep Foundation's (NSF) 2025 Sleep Awareness Week®.  Breescape is a firm believer that healthy sleep behaviors are key to happiness, productivity, and a fulfilling life, and hopes its new product will be part of the solution.

Available today nationwide on Amazon.com and Breescape.com, the Reversible Cooling Comforter will be available in select sizes and colors, including Mint Green, Soft Ivory, Snow White, Misty Grey and range from $109.99 to $199.99. For more information on other Breescape available products, see here.

About Breescape

Breescape, dedicated to providing innovative cooling sleep solutions for hot sleepers, is built on 45 years of home textile expertise as the sister brand of America's No. 1 online bedding brand, Bedsure. Our products are engineered to deliver lasting coolness, exceptional breathability, and unparalleled comfort. Designed to accommodate all sleepers and body types, our bedding offers full coverage, advanced cooling, moisture-wicking, and all-night breathability. This ensures uninterrupted, restorative sleep for everyone."

About Bedsure

Founded in 2016, Bedsure is a leading home textile brand with products sold to over 40 million customers worldwide. Currently, Bedsure has over 50 bestselling home products in 8 countries and has maintained a rapid growth rate for consecutive 9 years. While Bedsure has grown into a global company with diverse products to meet different customer needs, its focus on comfortable home products and everyday value stays the same. For more information, visit Bedsure's official website https://bedsurehome.com/, Amazon shop https://www.amazon.com/bedsure , or TikTok Shop https://vt.tiktok.com/ZT2Xvb2xW/?page=TikTokShop. Stay in touch with Bedsure on social media @bedsurehome.

[i] Circana, 2023.

[ii] Results based on 1000-person survey conducted by Breescape comparing it to other cooling products.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breescape™ Unveils Game Changing Reversible Cooling Comforter with BlendTek™ Technology for Unparalleled Temperature Control

TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening

TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance therapy

TAIPEI, March 18, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for HIV maintenance therapy. This regimen, which is the first of its kind, offers a viable alternative to daily oral cART for individuals living with HIV.

Key findings from the trial include durable viral suppression, with 94% of participants maintaining RNA levels below 50 copies/mL throughout the treatment period, while only the remaining 6% of participants recorded viral load of 59 copies/mL at end of 24-week treatment. No pre-defined virologic failure, which were defined as two consecutive viral load measurements above 50 copies/mL.

The treatment was well-tolerated, with no serious adverse events, no Grade 3 or Grade 4, or acute infusion reactions reported. Additionally, no participants experienced treatment-limiting immune responses to the combination therapy.

One of the more remarkable findings of TMB-365/TMB-380 is that it does not require susceptibility screening as the combination's broad breadth of activity and high potency, participants were not pre-screened for susceptibility to either bNAb featured for lowering the barrier to treatment access and ensures a wider range of individuals living with HIV can benefit from the therapy.

Additionally, the pharmacokinetic (PK) and immunological markers also support the potential for long-acting viral suppression and stable immune function. This Phase 2a clinical trial was not a double-blind placebo-controlled study, and therefore, no statistical p-values were reported.

"We are honored that our study was accepted for late-breaking presentation at CROI, highlighting the high scientific merit and groundbreaking nature of our results among numerous research studies, TMB-365/TMB-380 is the first long-acting mAb combination to achieve a high rate of viral suppression without screening requirements with robust potency, broad coverage and low resistance risk The regimen aims to reduce the frequency of daily dosing, while maintaining treatment's efficacy," said Dr. Jimmy Chang, CEO of TaiMed Biologics.

"The global HIV treatment market valued at approximately USD 30 billion annually, with long-acting treatments currently account for only 3% but are projected to increase to over 30-40% in the coming years. The outstanding Phase 2a results position TMB-365/TMB-380 as a frontrunner in this rapidly growing sector, offering clear advantages over existing long-acting treatment options," emphasized by Dr. Jimmy Chang.

TaiMed Biologics is actively seeking strategic collaborations with global pharmaceutical partners to support the commercialization of TMB-365/TMB-380. TaiMed Biologics welcomes opportunities to explore potential collaborations with global pharmaceutical partners to advance the commercialization of TMB-365/TMB-380

For more information, please contact: Jonathan Ho, jho@taimedbio.com.

About TaiMed Biologics

Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV and continues to pioneer long-acting biologics and antibody-drug conjugates (ADCs). TaiMed Biologics also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market since November 2015, currently part of the MSCI Small Cap Index.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025